Antibodies against amyloid beta (Aβ) protein deposits that are thought to play a role in Alzheimer's disease have shown some success in preventing the buildup of deposits in animals, but they have not been effective at removing preexisting deposits. Now researchers reporting in the December issue of the Cell Press journal Neuron show that a modified antibody was able to clear preexisting Aβ deposits in a mouse model of Alzheimer's disease.
"These findings have important implications for current and future development of antibodies for the treatment of Alzheimer's disease," says first author Ronald DeMattos, PhD, of Eli Lilly and Company.
One of the hallmarks of Alzheimer's disease is the accumulation between nerve cells of hard, insoluble protein fragments called amyloid plaques (or deposits). These plaques consist of Aβ fragments that are normally broken down and eliminated in the healthy brain. Emerging literature suggests that extensive plaque deposition occurs in Alzheimer's disease patients some 10 years prior to first memory complaint, and by the time of diagnosis, plaque deposition is already reported to be at or near maximal levels.
Immunotherapy for Alzheimer's disease is a promising therapeutic approach that uses antibodies to target and clear Aβ that exists as a soluble peptide or within insoluble deposits. Thus far, many investigators have utilized antibodies that can bind both soluble and insoluble forms of Aβ. These antibodies are effective in reducing amyloid deposition in mice prone to developing plaques, when given as a preventative measure; however, when given to aged mice with preexisting plaques, they have little or no effect and often cause severe side effects.
Dr. DeMattos and his colleagues hypothesized that these antibodies are unable to remove existing plaques because they become saturated with soluble Aβ when they enter the brain, and as such they are not able to bind to their intended target. To test this hypothesis, they developed a genetically engineered antibody that selectively targets the plaques.
The Lilly researchers found that their plaque-specific antibody crossed the blood-brain barrier, bound to deposited beta amyloid, and caused robust clearance of preexisting plaques in mice without causing microhemorrhage. A comparator antibody that bound to both soluble and insoluble Aβ did not effectively lower existing plaques yet caused an increase in microhemorrhage. "The data suggest that an antibody that binds to only insoluble amyloid beta is likely critical for plaque removal without the associated adverse event of microhemorrhage," says Dr. DeMattos.
The Lilly researchers believe these results are consistent with their original hypothesis. "Target engagement is fundamental for the clearance of deposited plaques, and these results highlight that approaches aimed at increasing antibody binding, or target engagement, will result in significant plaque clearance," says Dr. DeMattos.
The findings may help explain why the Alzheimer's drug bapineuzumab was no better than placebo in two recent late-stage trials in patients who had mild to moderate Alzheimer's disease. Bapineuzumab binds to both soluble and insoluble beta amyloid.
Cell Press: http://www.cellpress.com
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?
It is only in the aftermath of treatment that survivors discern that their adrenalin alone wont fuel the rest of their recovery. For many, surviving cancer is followed by even more hardship
Just down the road from Facebook and Google, Dr. Phil Wagner runs a laboratory dedicated to optimizing the performance of some of the world's top athletes. At Sparta Performance Science in Menlo Park, California, Wagner and his team bring the spirit of Silicon Valley to bear on the athletic world, helping athletes find the tiny advantages that add to championships. Join us for a trip inside the lab to see where sports meets science.
Pieter Cohen, an internist in Massachusetts, got interested in dietary supplements several years ago, when some of his …
The risk of overdiagnosis and false positives means the UK may be barking up the wrong tree in trialling a wider target age range for breast screening